1 Min Read
Nov 21 (Reuters) - Genentech:
* GENENTECH - FDA GRANTED ACCELERATED APPROVAL TO VENCLEXTA, IN COMBINATION WITH A HYPOMETHYLATING AGENT, OR LOW-DOSE CYTARABINE IN NEWLY-DIAGNOSED AML Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.